Dapagliflozin in heart failure with slightly reduced or preserved ejection fraction | NEJM

Of the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (SDS, BC, ASD, MV); the British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom (JJVM, PSJ); the Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen (RAB, CSPL) and Haga Academic Hospital, The Hague (CJWB) — both in the Netherlands; the University of Wisconsin, Madison (D. DeMets); Duke University Medical Center, Durham, NC (AFH); Yale School of Medicine, New Haven, CT (SEI); Saint Luke’s Mid America Heart Institute, University of Missouri, Kansas City, Kansas City (MNK); National Heart Center Singapore and Duke-National University of Singapore, Singapore (CSPL); National University of Cordoba, Cordoba (FM), and Jefe de Unidad de Insuficiencia Cardíaca, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Buenos Aires (JT) — both in Argentina; Northwestern University Feinberg School of Medicine, Chicago (SJS); General University Hospital, Charles University, Prague, Czech Republic (JB); General Clinical Research Center and Department of Cardiology, Taipei Veterans General Hospital and National Yang Ming Chiao Tung University, Taipei, Taiwan (C.-EC); the Department of Cardiology, Bellvitge University Hospital and Bellvitge Biomedical Research Institute, University of Barcelona, ​​​​L’Hospitalet de Llobregat, Barcelona (JC-C.); George Emil Palade University of Medicine, Pharmacy, Science and Technology, Târgu Mureş, Romania (D. Dobreanu); the Department of Cardiology, Lodz Medical University, Lodz, Poland (JD); University of Utah, Salt Lake City (JCF) Medical Center; Centro de Estudios Clínicos de Queretaro, Queretaro, Mexico (MAA-G.); the Department of Cardiac Sciences, King Saud University, Riyadh, Saudi Arabia (WAH); the Cardiovascular Research Institute and the Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China (YH); Clinica Vesalio, San Borja, Peru (JWCH); the Department of Cardiovascular Diseases, Cardiac Intensive Care, University Hospitals Leuven, Leuven, Belgium (SPJ); the Department of Non-invasive Cardiology, National Cardiology Hospital, Sofia, Bulgaria (TK); Kinshukai Hanwa Daini Senboku Hospital, Osaka, Japan (MK); Cardiovascular Center, Semmelweis University, Budapest, Hungary (BM); Institut de Cardiologie de Montréal, Université de Montréal, Montreal (EO), and the Department of Cardiac Surgery, St. Michael’s Hospital, University of Toronto, Toronto (SV) — both in Canada; the Cardiovascular Department, Instituto de Pesquisa Clínica de Campinas, Campinas, Brazil (JFKS); the Department of Myocardial Disease and Heart Failure, National Medical Research Center for Cardiology, Moscow (SNT); the Minneapolis Veterans Affairs Center for Care Delivery and Outcomes Research, University of Minnesota, Minneapolis (OV); Cardiovascular Center, Tam Anh Hospital, Tan Tao University, Tan Duc, Vietnam (VNP); and late stage development, cardiovascular, renal and metabolism, biopharmaceutical research and development, AstraZeneca, Gothenburg, Sweden (UW, NZ, EB, DL, MP, AML).